Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EPIPHARM

Financiado

Development of a ncRNA DNA Methylation Kit for Treatment Guidance in Cancer of U...

Development of a ncRNA DNA Methylation Kit for Treatment Guidance in Cancer of Unknown Primary The innovative idea behind the EPIPHARM (EPIgenetics of PHARMacogenetics) project is to develop a package demonstrating the feasibility of a high-throughput tool for epigenotyping Cancer of Unknown Primary (CUP) to identify a drug... ver más

31/07/2018

FUNDACIO INSTITUT...

149K€

Presupuesto del proyecto: 149K€

Líder del proyecto

FUNDACIO INSTITUT D?INVESTIGACIO BIOMEDICA DE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-07-31

ERC-PoC-2016: ERC-Proof of Concept-2016

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

FUNDACIO INSTITUT D?INVESTIG...

119.35K€ | Lider

CONSTRUCCIONES ELECTROMECANI...

187.14K€ | Participante

XENOPAT

30.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

OR-HMC Assay for cancer diagnostics by quantification of 5hmC 150K€ Cerrado

SAF2009-08663 CARACTERIZACION EPIGENOMICA DE LAS NEOPLASIAS HEMATOLOGICAS 114K€ Cerrado

EUIN2017-87335 DESARROLLO DE NUEVAS TECNICAS PARA LA DETECCION Y CUANTIFICA... 10K€ Cerrado

EpiCancer Comprehensive Platform for the Functional Characterization o... 2M€ Cerrado

RTC-2017-6685-1 Desarrollo de un kit basado en el sistema GEUS para el diagn... 914K€ Cerrado

EpiCblood Towards early cancer detection and tumor classification usin... 1M€ Cerrado

Duración del proyecto: 21 meses Fecha Inicio: 2016-10-10
Fecha Fin: 2018-07-31

Líder del proyecto

FUNDACIO INSTITUT D?INVESTIGACIO BIOMEDICA DE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Presupuesto del proyecto 149K€

Descripción del proyecto The innovative idea behind the EPIPHARM (EPIgenetics of PHARMacogenetics) project is to develop a package demonstrating the feasibility of a high-throughput tool for epigenotyping Cancer of Unknown Primary (CUP) to identify a drug sensitivity fingerprint based in the DNA methylation profile of non-coding RNA (ncRNA) loci. CUPs are a heterogeneous group of cancers defined by the presence of metastatic disease with no identified primary tumor at presentation. The CUP outcome is extremely poor with an expected death within the first six months of the diagnosis. CUP has been reported to comprise approximately 5% of all cancer cases in the world. Despite the introduction of new image technologies and immunohistochemistry methods, more than 50% of CUPs remain anonymous regarding their primary tumor site of origin and, as mentioned, their prognoses are dismal. For most patients with CUP, recommended treatments involves just empiric chemotherapy, usually with a taxane/platinum or gemcitabine/platinum regimens that achieve the described modest clinical benefit. Thus, it is necessary to have better tools to guide the pharmacological treatment of CUP cases. As part of the ERC Advanced Grant Epigenetic Disruption on Non-Coding RNAs in Human Cancer (EPINORC) we identified CpG methylation changes in a wide variety of ncRNAs (microRNAs, lincRNAs, T-UCRs, snoRNAs, piRNAs...) that showed a tumor-type specific pattern that has allowed the successful development of the EPICUP assay for the diagnoses of CUPs that it has been licensed and it is undergoing final clinical validation. In the current EPIPHARM Proof of Concept (PoC) proposal, we plan to optimize a ncRNA DNA methylation assay that includes a user-friendly and cost effective approach to improve the therapy of CUP cases by providing a more personalized drug treatment to an extent that will make it interesting commercially for the health providers and their associated company partners.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores